Parataxis Korea, Inc. (288330.KQ)
KOSDAQ · KRW · Financial Services · Capital Markets
₩416 (+0.00%) as of
Key statistics
- Market cap
- 44.13B
- Dividend yield
- 0.00%
- 52-week range
- 392.00 – 1,608.00
- Beta
- 1.68
- Revenue (TTM)
- 1.59B
- Profit margin
- 0.00%
About Parataxis Korea, Inc.
Parataxis Korea, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration with Atomwise to launch small molecule programs across various therapeutic areas using structure-based AI technology for drug discovery; the University of Colorado School of Medicine to explore the potential of BBT-877 for immuno-oncology; and the Emory University School of Medicine to explore combination therapy of BBT-877 for KRAS/P53 mutant NSCLC patients resistant to anti-PD-1 blockade. The company was formerly known as Bridge Biotherapeutics, Inc. and changed its name to Parataxis Korea, Inc. in August 2025. The company was founded in 2015 and is headquartered in Seongnam-si, South Korea.
- Sector
- Financial Services
- Industry
- Capital Markets
- Headquarters
- Seongnam-si, South Korea
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.